[{"address1": "171 Oyster Point Boulevard", "address2": "Suite 400", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 489 9000", "website": "https://www.surrozen.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.", "fullTimeEmployees": 42, "companyOfficers": [{"maxAge": 1, "name": "Mr. Craig C. Parker M.B.A.", "age": 62, "title": "CEO, President & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 825320, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles  Williams", "age": 44, "title": "CFO, COO & Corporate Secretary", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 611028, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Li  Yang Ph.D.", "age": 55, "title": "Executive Vice President of Research", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 535463, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. K. Christopher  Garcia Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roeland  Nusse Ph.D.", "age": 74, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Calvin  Kuo M.D., Ph.D.", "title": "Co-Founder & Member of Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Esther  Jhun", "title": "Controller", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.1, "open": 11.545, "dayLow": 10.4099, "dayHigh": 11.65, "regularMarketPreviousClose": 11.1, "regularMarketOpen": 11.545, "regularMarketDayLow": 10.4099, "regularMarketDayHigh": 11.65, "forwardPE": -0.9719888, "volume": 15973, "regularMarketVolume": 15973, "averageVolume": 44865, "averageVolume10days": 31270, "averageDailyVolume10Day": 31270, "ask": 10.9, "askSize": 100, "marketCap": 33830416, "fiftyTwoWeekLow": 6.0, "fiftyTwoWeekHigh": 18.17, "priceToSalesTrailing12Months": 3.3830416, "fiftyDayAverage": 11.48482, "twoHundredDayAverage": 10.14962, "currency": "USD", "enterpriseValue": 4118480, "floatShares": 1131672, "sharesOutstanding": 3249800, "sharesShort": 149231, "sharesShortPriorMonth": 45377, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.045900002, "heldPercentInsiders": 0.0167, "heldPercentInstitutions": 0.76972, "shortRatio": 2.75, "shortPercentOfFloat": 0.0617, "impliedSharesOutstanding": 3465200, "bookValue": 1.756, "priceToBook": 5.928246, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -44438000, "trailingEps": -16.94, "forwardEps": -4.45, "lastSplitFactor": "1:15", "lastSplitDate": 1702512000, "enterpriseToRevenue": 0.412, "enterpriseToEbitda": -0.165, "52WeekChange": 0.13770497, "SandP52WeekChange": 0.19995654, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SRZN", "underlyingSymbol": "SRZN", "shortName": "Surrozen, Inc.", "longName": "Surrozen, Inc.", "firstTradeDateEpochUtc": 1610375400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f300e438-31d2-353a-a98a-8e2cc4bb3308", "messageBoardId": "finmb_401948183", "gmtOffSetMilliseconds": -18000000, "currentPrice": 10.41, "targetHighPrice": 45.0, "targetLowPrice": 32.0, "targetMeanPrice": 38.5, "targetMedianPrice": 38.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 31012000, "totalCashPerShare": 9.607, "ebitda": -25022000, "totalDebt": 1527000, "quickRatio": 7.06, "currentRatio": 7.4, "totalRevenue": 10000000, "debtToEquity": 26.945, "revenuePerShare": 3.804, "returnOnAssets": -0.32645, "returnOnEquity": -1.73593, "grossProfits": -17230000, "grossMargins": -1.723, "ebitdaMargins": -2.5022001, "operatingMargins": 0.1232, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]